Post Reply
1001-1020 of 1197
I bet to differ. This time hv got exceptionally good news and price gapped up with moderately good volume.
I'm seeing it will retake back 13c this or next week
I'm seeing it will retake back 13c this or next week
sheerluck ( Date: 10-Apr-2018 12:15) Posted:
|
This one always same pattern. Jump on news and after 1-2 days back to square one.
Rally might not last. Take profit and run.
I started to load from 13.x to yesterday's 11.5
Finally can see my profit soon ... LOL
Finally can see my profit soon ... LOL
seems good.. hope they can repeat this feat once every few years.
NextEvolution ( Date: 10-Apr-2018 09:49) Posted:
|
Finally after so many weeks of selling, Trendlibes show it's most valuable asset with Braun....
The Trendlines Group Ltd. Discloses Stimatix GI Ltd. as Company Whose Assets Were Sold in 2014 Asset Purchase Agreement B. Braun Medical SAS is disclosed as acquirer of Stimatix?s assets MISGAV, Israel, 9 April 2018
-- The Trendlines Group Ltd. (the ?Company? or ?Trendlines? and together with its subsidiaries, the ?Group?) (SGX: 42T OTCQX: TRNLY), a leading Israeli investment and innovation commercialization company, focused on early-stage, high growth innovation-based medical and agricultural technologies, today named its colostomy-device company, Stimatix GI Ltd. (?Stimatix?), as the company referred to in its financial statements and other reports as its ?Most Valuable Portfolio Company?. In November 2014, Stimatix sold its assets to a subsidiary company of the B. Braun Group, B. Braun Medical SAS (?B. Braun?), which hosts the Stomacare Center of Excellence. B. Braun is one of the world's leading providers and manufacturers of healthcare solutions. B. Braun has advised Trendlines that it plans to market the product internationally from mid-2018. The 2014 Asset Purchase Agreement (?2014 APA?) included a non-disclosure agreement that prevented release of information now that the product is coming to market, B. Braun has authorized disclosure by Trendlines of the identity of the Most Valuable Portfolio Company and the fact that B. Braun was the acquirer. Trendlines currently maintains a 28.2% holding in Stimatix. As of the last valuation dated 31 December 2017, the fair value of Trendlines? Stimatix holding, was US$42.6 million. Due to the significant value of Stimatix in the Trendlines portfolio, the valuation of Stimatix is set by an independent firm that specializes in the medical device industry. The US$42.6 million valuation represents the projected net present value of Trendlines? share of the estimated future royalty payments from the sale of the company?s product, after adjusting the cash flow to take account of multiple risk factors including, market risk, manufacturing risk, and product risk, and then applying a financial discount rate. Further details on the aforementioned valuation can be found in ?Notes to the Financial Statements?, Note 8 B, page 116 of the Group?s audited financial statements for the financial year ended 31 December 2017.
The Trendlines Group Ltd. Discloses Stimatix GI Ltd. as Company Whose Assets Were Sold in 2014 Asset Purchase Agreement B. Braun Medical SAS is disclosed as acquirer of Stimatix?s assets MISGAV, Israel, 9 April 2018
-- The Trendlines Group Ltd. (the ?Company? or ?Trendlines? and together with its subsidiaries, the ?Group?) (SGX: 42T OTCQX: TRNLY), a leading Israeli investment and innovation commercialization company, focused on early-stage, high growth innovation-based medical and agricultural technologies, today named its colostomy-device company, Stimatix GI Ltd. (?Stimatix?), as the company referred to in its financial statements and other reports as its ?Most Valuable Portfolio Company?. In November 2014, Stimatix sold its assets to a subsidiary company of the B. Braun Group, B. Braun Medical SAS (?B. Braun?), which hosts the Stomacare Center of Excellence. B. Braun is one of the world's leading providers and manufacturers of healthcare solutions. B. Braun has advised Trendlines that it plans to market the product internationally from mid-2018. The 2014 Asset Purchase Agreement (?2014 APA?) included a non-disclosure agreement that prevented release of information now that the product is coming to market, B. Braun has authorized disclosure by Trendlines of the identity of the Most Valuable Portfolio Company and the fact that B. Braun was the acquirer. Trendlines currently maintains a 28.2% holding in Stimatix. As of the last valuation dated 31 December 2017, the fair value of Trendlines? Stimatix holding, was US$42.6 million. Due to the significant value of Stimatix in the Trendlines portfolio, the valuation of Stimatix is set by an independent firm that specializes in the medical device industry. The US$42.6 million valuation represents the projected net present value of Trendlines? share of the estimated future royalty payments from the sale of the company?s product, after adjusting the cash flow to take account of multiple risk factors including, market risk, manufacturing risk, and product risk, and then applying a financial discount rate. Further details on the aforementioned valuation can be found in ?Notes to the Financial Statements?, Note 8 B, page 116 of the Group?s audited financial statements for the financial year ended 31 December 2017.
This counter is in downtrend channel since February. It broke all the support levels and the price is still falling. Do not catch the falling knife. Avoid this counter at the moment and wait for the price to be stabilized.
testing 12cts......
anyone know why myp shares keep moving up
Inching up, slow and steadily. Tomorrow shall see if can test 13.5 wall and hold up there or higher. Then that will be an uptrend movement
This one really missing in action. I'm accumulating as low as 12.8 up to 13+. And sooner or later going to recoil back to 15+/-
For mid to longer term holding, not contra or intraday play
For mid to longer term holding, not contra or intraday play
Deng xiao ping :&rdquo don&rsquo t care black cat (FA) or white cat (TA), as long can catch Micky Mouse (Make money) will be a good cat (good A). 不 管 是 黑 猫 (FA) 白 猫 (TA),能 抓 老 鼠 (能 赚 大 钱 ),就 是 好 猫 (好 A)!😄 😄 😄 😄
Bro, u are using TA I'm using FA + TA.
But since hitting historical and intraday low of 12.7, it bounced back higher. If tomorrow another green day and long candle, reversal should be on the card
But since hitting historical and intraday low of 12.7, it bounced back higher. If tomorrow another green day and long candle, reversal should be on the card
sheerluck ( Date: 08-Mar-2018 12:42) Posted:
|
..stand by your lorri..its comg down
MarketSensors ( Date: 08-Mar-2018 13:38) Posted:
|
Keep dropping non stop! 😡 . Once it drops below 10 cents and I will send my lorries and load up the shares. 😓
This one must hold for ling term. But what is a good entry price? Previous 13.3cts support broken and it is now in new terrority.
A lot of people are skeptical on Trendlines, which is good for value investors who want to pick up cheaper share prices, which is what I've been doing last few days. It's on the top of watchlist now.
Their partnerships include who's who's in the industries, including SG healthcare, SG and Israel governments. That also include mega brands like Bayer and Braun from Germany, Haier from China and more.
Please DYODD, this counter good for mid to longer term holding, not short-term play
Their partnerships include who's who's in the industries, including SG healthcare, SG and Israel governments. That also include mega brands like Bayer and Braun from Germany, Haier from China and more.
Please DYODD, this counter good for mid to longer term holding, not short-term play
...everybody very careful now..as no concrete news to support the growth..jews are smart ppl we know..but have to wait maybe in 2-3 years time, i guess.
Huchin ( Date: 08-Mar-2018 00:28) Posted:
|
Post lots of update to SGX portal but no one seems to believing it.
..just like many of the penny stock, probably will go below 0.10..